Haisco Pharmaceutical (688302.SH): The Phase II clinical trial for the treatment of metabolic associated fatty liver disease (MASH) drug HP515 has completed the enrollment of the first batch of participants.

Oceanus Pharmaceuticals (688302.SH) announced that the Phase II clinical trial of HP515, a drug developed by the company for the treatment of metabolic associated fatty liver disease (MAFLD, formerly known as non-alcoholic fatty liver disease (NAFLD)), has recently completed the enrollment of the first batch of participants. As of the date of the announcement, there are no similar target products approved for marketing in China. HP515 tablets are orally administered highly selective thyroid hormone receptor beta (THR-) agonists developed by the company. HP515 tablets can directly act on THR- to activate downstream gene transcription, enhance hepatic lipid metabolism activity, improve liver fat metabolism, and reduce lipotoxicity to achieve improvement in metabolic associated fatty liver disease. HP515 was approved by the China National Medical Products Administration for use in metabolic associated fatty liver disease (MAFLD) in August 2024, and by the United States Food and Drug Administration for use in metabolic associated fatty liver disease (MAFLD) in September 2024.